AbCellera Biologics Inc.
ABCL· Nasdaq
Released Feb 24, 2022, after the close
10-K filed Feb 25, 2022, 56 days after period end · 0001564590-22-007077
derived · Computed from the longer spans the company filed.
| Metric | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures |
|---|---|---|
| Revenue | $139.31M | $207.91M |
| Net Income | $59.95M | $117.00M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
AbCellera Biologics Inc. · CIK 1703057 · Engraved from SEC EDGAR
ended Dec 31, 2021 · filed Feb 25, 2022 · 56 d after period end
+3.1% from the close of Feb 24, 2022 to the close of Feb 28, 2022, the first after the release.